Department of Nephrology, Hospital Perpetuo Socorro, Alicante, Spain.
J Nephrol. 2010 Sep-Oct;23(5):525-34.
Few studies have investigated nonadherence to phosphate binders. The aim of this study was to evaluate the degree of adherence of our hemodialysis (HD) patients to phosphate binders and to determine which variables were related to nonadherence to treatment.
In 165 HD patients, the degree of adherence to the drugs prescribed was studied using the Simplified Medication Adherence Questionnaire.
Of patients, 40% were nonadherent. Specific nonadherence to phosphate binder and hypotensive medication was admitted by 21% and 13% of patients, respectively. Nonadherent patients had significantly higher mean serum phosphorus (P) (4.7 ± 0.9 mg/dL vs. 4.4 ± 0.7 mg/dL; p=0.007) and potassium levels (6.3 ± 4.4 mEq/L vs. 5.3 ± 1.4 mEq/L; p=0.04). There was a statistically significant association between mean P levels >5.5 mg/dL in the last 6 months and nonadherence to treatment (X2=4.8; 95% confidence interval [95% CI], 1.0-6.6; p=0.02). No relationship was found between patients with blood pressure levels >140/90 mm Hg and nonadherence to hypotensive medication (X2=0.02; 95% CI, 0.2-4.1; p=0.88). Patients specifically nonadherent to phosphate binders were more likely to have P levels >5.5 mg/dL (X2=4.7; 95% CI, 1.07-6.5; p=0.03). No statistically significant association was found between patients noncompliant with hypotensive agents and those noncompliant with phosphate binders (X2=0.39; 95% CI, 0.4-4.7; p=0.53). There were no significant differences between adherent and nonadherent patients in terms of age, time on hemodialysis, Charlson Comorbidity Index, number of drugs prescribed and number of tablets per day (p>0.05).
Nonadherence to pharmacological treatment in dialysis patients is high. Nonadherence to phosphate binders was greater than for hypotensive agents, did not coexist in the same patients and had a greater impact on target achievement.
鲜有研究调查过磷酸盐结合剂的不依从性。本研究旨在评估我们血液透析(HD)患者对磷酸盐结合剂的依从程度,并确定哪些变量与治疗不依从有关。
在 165 名 HD 患者中,使用简化用药依从性问卷评估了药物的依从程度。
40%的患者不依从。分别有 21%和 13%的患者明确承认不依从磷酸盐结合剂和降压药物。不依从的患者血清磷(P)水平显著升高(4.7±0.9mg/dL 比 4.4±0.7mg/dL;p=0.007)和钾水平(6.3±4.4mEq/L 比 5.3±1.4mEq/L;p=0.04)。在过去 6 个月中,平均 P 水平>5.5mg/dL 与治疗不依从之间存在统计学显著关联(X2=4.8;95%置信区间[95%CI],1.0-6.6;p=0.02)。血压水平>140/90mmHg 的患者与不依从降压药物之间未发现相关性(X2=0.02;95%CI,0.2-4.1;p=0.88)。明确不依从磷酸盐结合剂的患者更有可能出现 P 水平>5.5mg/dL(X2=4.7;95%CI,1.07-6.5;p=0.03)。不依从降压药物的患者与不依从磷酸盐结合剂的患者之间无统计学显著相关性(X2=0.39;95%CI,0.4-4.7;p=0.53)。在年龄、血液透析时间、Charlson 合并症指数、开处方药物数量和每天服用片剂数量方面,依从与不依从的患者之间无显著差异(p>0.05)。
透析患者对药物治疗的依从性很高。对磷酸盐结合剂的不依从性大于对降压药物的不依从性,不会同时存在于同一患者中,并且对目标的实现影响更大。